Last updated: 2026-11-13 15:42:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Altimmune, Inc. (ALT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.62, with a market capitalization of $313.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.59 to $6.44. This page covers its latest market performance, valuation, price trends and company information.
$313.17M | |
$1.63 | |
$1.65 | |
$1.59 | |
$1.61 | |
1.42M | |
3.93M | |
-- | |
$6.44 | |
$1.59 | |
-- | |
-- |
Altimmune, Inc. (ALT) is currently trading at $1.62 as of 2026-11-13 15:26:56, up 0.62% ($0.01) from the previous close of $1.61
During today's regular trading session, ALT has traded between $1.59 and $1.65, with a trading volume of 1.42M shares. The current price is near the middle of today's range.
ALT is down 1.82% during regular trading hours.
Over the past seven days, Altimmune, Inc. (ALT) moved from $1.97 to $1.62, representing a decline of 18.02% ($0.36).
The stock traded between $1.59 and $2.21 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 4.39 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.6%
ALT is currently trading at $1.62, placing it 0.6% of the way from its 52-week low of $1.59 to its 52-week high of $6.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Altimmune, Inc. and ALT stock.
Altimmune (NASDAQ:ALT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 15.38 percent. This is a 28.57 percent increase over losses of $(0.21) per share from the
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profilePublication of results provides
Eligible investors can buy real shares of Altimmune, Inc. (ALT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ALT, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ALT shares and USD.
ALT Shares to USD
1.00 ALT shares = 1.615 USD
Calculations are estimates based on the latest available price and are for reference only.
